Effect of Efpeglenatide on Cardiovascular Outcomes

Exclusion Criteria

• •Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting.
• •History of chronic pancreatitis or acute idiopathic pancreatitis or diagnosis of any type of acute pancreatitis within 3 months prior to screening.
• •Personal or family history of medullary thyroid cancer.
• •Hypertension (with a systolic blood pressure \>180 millimeters of Mercury \[mmHg\] and/or diastolic blood pressure \>100 mmHg).
• •Hospitalization for hypertensive emergency within 3 months prior to randomization.
• •Planned coronary procedure or surgery after randomization.
• •No documented ophthalmologic exam with fundoscopy within 6 months prior to randomization.
• •Retinopathy or maculopathy with treatment, either recent (3 months prior to randomization) or planned during the study.
• •Treated with any glucagon-like peptide-1 receptor agonist product alone (eg, exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, semaglutide) or in combination within 3 months prior to screening.
• •Use of any Dipeptidyl peptidase 4 inhibitor within 3 months prior to screening.
• •Antihyperglycemic treatment had not been stable within 3 months prior to screening.
• •The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.